Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of cladabine in preparation of medicine for preventing or treating psoriasis

A technology for preparing medicines and psoriasis, which is applied to cladribine single-dose preparations and drug combinations. In the field of preparation of medicines for the prevention or treatment of psoriasis, cladribine can solve the difficulties in the treatment of psoriasis that cannot be completely cured , easy to relapse and other problems

Pending Publication Date: 2022-04-08
BEIJING TSINGHUA CHANGGUNG HOSPITAL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Psoriasis is usually difficult to treat, cannot be completely cured, and is prone to recurrence

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cladabine in preparation of medicine for preventing or treating psoriasis
  • Application of cladabine in preparation of medicine for preventing or treating psoriasis
  • Application of cladabine in preparation of medicine for preventing or treating psoriasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0086] Embodiment 1: the establishment of psoriasis mouse model

[0087] (1) The mice were anesthetized by intraperitoneal injection of pentobarbital sodium (80mg / kg), and the back hair was shaved with a children's hair shaver to form an exposed area with a size of about 2cm×3cm, and the hair removal area was treated with depilatory cream;

[0088] (2) After feeding in a single cage for 1 day, apply 62.5 mg / day imiquimod cream (5% mass fraction) for 14 days;

[0089](3) According to the PASI score of the control group to determine whether the model is successful or not, it was found that there was a significant difference in the PASI score of the psoriasis mouse model (pfigure 1 shown.

Embodiment 2

[0090] Embodiment 2: the in vitro experiment of mouse model

[0091] (1) Randomly divide the psoriasis mouse model successfully constructed in Example 1 into a model group, a cladribine high-dose group (abbreviated as a high-dose group), a cladribine low-dose group (abbreviated as a low-dose group), and a positive Drug methotrexate group, 10 mice in each group, and 10 normal mice were selected as the normal control group, marked and reared in a single cage in an independent ventilated cage;

[0092] (2) Carry out group treatment to mice, the opportunity of this treatment is the first day after the psoriasis mouse model of embodiment 1 is constructed successfully, wherein, cladribine high-dose group uses cladribine with 30mg / kg / The injection amount of d is carried out intravenous injection to mice, cladribine low-dose group is carried out intravenous injection to mice with cladribine injection amount with 20mg / kg / d, positive drug methotrexate group is with methotrexate The mi...

Embodiment 3

[0098] Example 3: Flow Cytometry Detection

[0099] Th1, Th2, Th17, Treg cytokines in the mouse serum extracted at 25 days in Example 2 were detected by flow cytometry, see for details Figure 3-28 . in, Figure 8 , 14 Among -15, 21, 27-28, * means there is a significant difference compared with the normal control group (p<0.05), ** means there is a very significant difference compared with the normal control group (p<0.01), # means There is a significant difference (p<0.05) compared with the psoriasis model group, ## indicates that there is a very significant difference (p<0.01) compared with the psoriasis model group.

[0100] For the detection results of Th1 cells, see Figure 3-8 . The results showed that compared with the normal control group, the proportion of Th1 cells in the psoriasis model was significantly increased. The ratio is reduced. Therefore, cladribine can significantly alleviate the phenomenon of increased Th1 cells caused by psoriasis.

[0101] For ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of cladribine in preparation of a medicine for preventing or treating psoriasis. The medicine can effectively treat psoriasis, and by using the medicine, the content of Th1 and / or Th17 cells in the body of a subject can be reduced, and the content of Th2 and / or Treg cells in the body of the subject can be increased.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, in particular to a use of cladribine in the preparation of a drug for preventing or treating psoriasis, more specifically to a use of cladribine in the preparation of a drug for preventing or treating psoriasis Uses, cladribine single-dose formulations and drug combinations. Background technique [0002] Psoriasis is an immune-mediated chronic relapsing inflammatory skin disease with typical clinical manifestations of scaly erythema or plaques. According to epidemiological survey results, the prevalence of psoriasis is on the rise. Psoriasis is usually difficult to treat, cannot be completely cured, and is prone to recurrence. [0003] Therefore, there is an urgent need to explore and develop a drug for the prevention or treatment of psoriasis. Contents of the invention [0004] The present invention aims to solve at least one of the technical problems existing in the prior art at least ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7076A61K45/06A61P17/06
Inventor 赵邑薛婧雯
Owner BEIJING TSINGHUA CHANGGUNG HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com